Obesity and COVID-19: A Virchow's Triad for the 21st Century

Carl J. Vaughan; Heather Cronin; Paul MacDaragh Ryan; Noel M. Caplice

doi:10.1055/s-0040-1714216

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2020; 120(11): 1590-1593
DOI: 10.1055/s-0040-1714216

Letter to the Editor

Obesity and COVID-19: A Virchow's Triad for the 21st Century

Autoren

Carl J. Vaughan

¹Department of Cardiology, Mercy University Hospital, Cork, Ireland
Heather Cronin

¹Department of Cardiology, Mercy University Hospital, Cork, Ireland
Paul MacDaragh Ryan

²Centre for Research in Vascular Biology, APC Microbiome Institute, University College Cork, Cork, Ireland

³Department of Cardiology, Cork University Hospital, Cork, Ireland
Noel M. Caplice

²Centre for Research in Vascular Biology, APC Microbiome Institute, University College Cork, Cork, Ireland

³Department of Cardiology, Cork University Hospital, Cork, Ireland

Abstract

Volltext

Referenzen

References
1 Zhu N, Zhang D, Wang W. et al; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382 (08) 727-733
2 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506
3 Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395 (10229): 1033-1034
4 Richardson S, Hirsch JS, Narasimhan M. et al; and the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020; 323 (20) 2052-2059
5 Dixon AE, Peters U. The effect of obesity on lung function. Expert Rev Respir Med 2018; 12 (09) 755-767
6 Nie W, Zhang Y, Jee SH, Jung KJ, Li B, Xiu Q. Obesity survival paradox in pneumonia: a meta-analysis. BMC Med 2014; 12: 61
7 Rello J, Storti E, Belliato M, Serrano R. Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers. Eur Respir J 2020; 55 (05) 2001028
8 Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. COVID-19 does not lead to a “typical” acute respiratory distress syndrome. Am J Respir Crit Care Med 2020; 201 (10) 1299-1300
9 Ryan PM, Caplice NM. Is adipose tissue a reservoir for viral spread, immune activation, and cytokine amplification in coronavirus disease 2019?. Obesity 2020; 28 (07) 1191-1194
10 Rovina N, Akinosoglou K, Eugen-Olsen J, Hayek S, Reiser J, Giamarellos-Bourboulis EJ. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit Care 2020; 24 (01) 187
11 Bikdeli B, Madhavan MV, Jimenez D. et al; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol 2020; 75 (23) 2950-2973
12 Fogarty H, Townsend L, Ni Cheallaigh C. et al. More on COVID-19 coagulopathy in Caucasian patients. Br J Haematol 2020; 189 (06) 1060-1061
13 Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181 (02) 271-280
14 Gheblawi M, Wang K, Viveiros A. et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ Res 2020; 126 (10) 1456-1474
15 Shoemaker R, Tannock LR, Su W. et al. Adipocyte deficiency of ACE2 increases systolic blood pressures of obese female C57BL/6 mice. Biol Sex Differ 2019; 10 (01) 45
16 Vlaicu SI, Tatomir A, Rus V. et al. The role of complement activation in atherogenesis: the first 40 years. Immunol Res 2016; 64 (01) 1-13
17 Magro C, Mulvey JJ, Berlin D. et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 2020; 220: 1-13
18 Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med 2020; 382 (17) 1653-1659
19 Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest 2017; 127 (01) 1-4
20 Blokhin IO, Lentz SR. Mechanisms of thrombosis in obesity. Curr Opin Hematol 2013; 20 (05) 437-444
21 Oxley TJ, Mocco J, Majidi S. et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med 2020; 382 (20) e60
22 Mahmud E, Dauerman HL, Welt FG. et al. Management of acute myocardial infarction during the COVID-19 pandemic. J Am Coll Cardiol 2020;
23 ClinicalTrials.gov. NCT04322773: Anti-il6 treatment of serious COVID-19 disease with threatening respiratory failure (TOCIVID). 2020 ; Available at: https://clinicaltrials.gov/ct2/show/NCT04322773 . Accessed May 5, 2020